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Pharmacological therapy can influence morbidity and mortality in severe chronic obstructive pulmonary disease 
(COPD). Long-term domiciliary oxygen therapy (LTOT) improves survival in COPD with chronic hypoxaemia. 
Oral steroid medication has been associated with improved survival in men and increased mortality in women, while 
inhaled steroid medication has been associated with a reduction in the exacerbation rate. We have analysed the 
relationships between pharmacological therapy including oxygen therapy, sex, performance status and need for 
hospitalization and mortality in 403 patients with COPD (201 men) after their registration in a national oxygen 
register for LTOT. The mean value of days spent in hospital per year was 44. An increased need of hospital care was 
independently predicted by a poor performance status, high age and, in women, orally administered steroid 
medication. Hospital admissions were significantly longer in the terminal stage of COPD among women receiving 
oral steroid medication. Increased mortality was predicted by a poor performance status and, in women, oral steroid 
treatment. Predictors of morbidity and mortality during LTOT were found to coincide. The increased mortality in 
women receiving oral steroid medication was found to be associated with an increased need of hospital care due to 
longer hospital stays during the terminal stage of the disease. When analysing effects and side-effects of steroid 
medication in COPD, the possibility of sex-related differences should be considered. 
RESPIR. MED. (1998) 92, 50-56 
Introduction 
Long-term domiciliary oxygen therapy (LTOT) improves 
survival and the quality of life of patients with stable 
chronic hypoxaemia caused by chronic obstructive pul- 
monary disease (COPD) (l-3). Death is often caused by 
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acute or chronic respiratory failure (4). Patients with COPD 
who fulfil the criteria for LTOT have advanced disease and 
usually receive regular medication with bronchodilators, 
often in combination (5,6). The majority of patients also 
receive daily diuretic medication (6). Several mechanisms 
have been suggested by which these medications might 
influence the frequency or duration of exacerbations of 
COPD. In COPD with less advanced airway obstruction, it 
has been suggested that corticosteroid medication reduces 
the decline of FEV,, leading eventually to respiratory 
failure (7,8). We have reported an increased mortality 
among women with COPD receiving oral steroid medi- 
cation during LTOT (9). It has also been suggested that 
inhaled corticosteroids might reduce the exacerbation rate 
in COPD (10). Digoxin has been ascribed a negative effect 
on neutrophil mobilization in experimental pneumococcal 
pneumonia, a common pathogen in COPD (11). Digoxin 
and bronchodilators such as &agonists (12,13) and theo- 
phylline (14,15) have been ascribed effects which might 
theoretically influence lung defences and, consequently, 
the frequency or duration of deteriorations in COPD 
(4). There is, therefore, a possibility that apart from 
disease severity and oxygen therapy, concomitant 
medication might influence morbidity and mortality during 
LTOT. 
0 1998 W. B. SAUNDERS COMPANY LTD 
HOSPITALCAREANDMORTALITYDURING LTOT 51 
The associations between patient characteristics and oxy- 
gen, bronchodilator and corticosteroid medication on days 
spent in hospital due to respiratory disease and survival was 
analysed in a population of COPD patients who have been 
followed prospectively in the Swedish Oxygen Register 
since the start of their LTOT (9). Analyses were performed 
separately in men and women, as well as in both sexes 
together. 
Methods 
The baseline data of the patient population, a shorter 
follow-up of survival (9) and the organization of the 
Swedish Oxygen Register (6) have already been described in 
detail and will only be presented briefly here. The register 
covers 85590% of all adult patients treated with LTOT for 
chronic hypoxaemia in Sweden. There are no exclusion 
criteria. With few exceptions, LTOT is started in hospital 
and supervised on outpatient visits to chest clinics. Accord- 
ing to the Swedish guidelines for LTOT, oxygen therapy 
is recommended after an assessment of the stability of 
hypoxaemia during a period of 3 weeks during a stable 
period in the disease. The cut-off point for hypoxaemia was 
of around 7.5 kPa (6) and a resting PaO, of above 8 kPa, 
preferably above 9 kPa, during oxygen breathing was rec- 
ommended. The clinical data recorded at the start of LTOT 
included cause(s) of hypoxaemia, arterial blood gas ten- 
sions when breathing air and oxygen, each for a minimum 
of 20 min, FEV,, FVC, haematocrit, World Health 
Organization (WHO) performance status (16) and smoking 
habits. The presence or absence of the following medi- 
cations was recorded: inhaled &agonists, oral &-agonists, 
inhaled steroids, oral steroids, theophylline, digitalis, anti- 
coagulants, diuretics and calcium antagonists. The patients 
have been followed-up in half-yearly reports to the Oxygen 
Register with registration of medication, date and cause of 
withdrawal of LTOT and days spent in hospital due to 
respiratory disease. 
During the period 1 January 1987 to 30 June 1989, 403 
patients (201 males) were registered as starting LTOT for 
chronic hypoxaemia caused solely by COPD (9,17). Oxygen 
was prescribed for a mean of 18 h day - i at the start of 
LTOT. Concentrators were used by 65% of the patients at 
baseline, and high-pressure compressed gas cylinders were 
used by the remaining patients. Small oxygen cylinders 
were available for ambulation. All the patients gave their 
informed consent. The register was approved by the 
Swedish Board of Health and Welfare, all the regional 
Ethics Committees and the Data Inspection Board. 
STATISTICAL ANALYSIS 
For comparisons between groups and univariate survival 
analysis, the Quest database program was used (18). Com- 
parisons between groups were performed using Student’s 
t-test. Comparisons between more than two groups were 
performed using one-way analysis of variance (ANOVA) 
and Spearman’s rank correlation. The influence of age, sex, 
arterial blood gas tensions when breathing air and oxygen, 
TABLE 1. Characteristics of patients with chronic obstruc- 
tive pulmonary disease starting long-term oxygen therapy 
by sex (mean & SD) (n=403) 
Characteristic 
Men Women 
(n=201) (n=202) P value 
Age (years) 
PaO, (air) (kPa) 
PaCO, (air) (kPa) 
FEV, (1) 
FEV, (% predicted) 
FVC (1) 
FVC (% predicted) 
68 i 9 66xt 8 co.01 
6.6 * 1.1 6.6 zk 1.1 0.56 
6.4 zk 1.3 6.6 * 1.1 0.25 
0.8 * 0.4 0.6 rt 0.2 co.01 
27ziz 15 21* 11 >0.8 
2.2 rt 0.9 1.5 k 0.6 co.01 
50 zk 20 51* 18 0.64 
PaO, (air), arterial 0, tension when breathing air; PaCO, 
(air), arterial CO, tension when breathing air. 
smoking history, spirometry volumes, WHO performance 
status and medication on survival was analysed using the 
KaplanMeier method. A log-rank Chi-square test was 
used for the comparison of survival between groups (19). 
Confidence limits for the relative risks were calculated 
according to Miettinen (20). Multiple linear regression was 
used to analyse the relationship between the following 
baseline variables and days spent in hospital per year: age, 
sex, smoking history, WHO performance status, arterial 
blood gas tensions while breathing air, FEV,, FVC and 
medication. For multivariate survival analysis, Cox’s pro- 
portional hazards model was used. The relationship 
between the same baseline variables and overall mortality 
was analysed in the multivariate analysis. 
Regressions were performed in a backward stepwise 
manner. The entry limit was set at P=O.l and the exit limit 
at P=O.15. The survival analyses were also performed 
separately in men and women including the same baseline 
variables apart from sex. Spirometry data was missing in 
23% of the patients, and analyses were also performed with 
and without spirometry data in the model. In all, six 
multivariate analyses of survival were performed. 
Patients who were withdrawn from LTOT due to an 
improvement in hypoxaemia or a lack of co-operation were 
withdrawn from the analyses of survival on the day of 
withdrawal from LTOT. A two-sided P value of ~0.05 was 
accepted as significant. 
Results 
The details of the study population, 403 patients (201 men) 
with chronic hypoxaemia caused solely by COPD, have 
been given elsewhere (9,17). The patients have been 
followed-up for a mean of 2.6 yr (range: 1 day-7.5 years). 
The surviving patients have been followed-up for a mean of 
6 yr (range: 5-7.5 years). Women started LTOT at a 
younger age than men (P=O.O03) (Table 1). Men and 
women who were not receiving oral steroid medication 
started LTOT at a similar age, 67 & 9 vs 66 & 8 years. Men 
receiving oral steroid medication were older than women 
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TABLE 2. Pharmacological therapy in patients starting long- 
term oxygen therapy by sex (n=403) 
Medication 
Men 
(n=201) 
Women 
(n=202) 
Inhaled p-agonist (%) 88 87 
Oral P-agonist (%) 58 62 
Theophylline (%) 82 73 
Inhaled corticosteroid (%) 49 51 
Oral corticosteroid (%) 50 52 
Digitalis (%) 29 28 
Diuretic (%) 71 82 
Calcium antagonist (%) 29 28 
Anticoagulant (%) 2 2 
receiving oral steroid medication (70 & 7 vs 67 & 8 years) 
(P<O.OOl). Men receiving oral steroids were older at the 
start of LTOT than men not receiving oral steroids 
(P=O.Ol). There were no significant differences between 
patients receiving and not receiving oral steroid medication 
in terms of arterial blood gas tensions, spirometry values or 
performance status. Fifty percent of the patients on oral 
steroids at the start of LTOT were still on oral steroids after 
6 months of follow-up. 
The proportion of patients using the listed medication are 
shown in Table 2. There was no statistically significant 
difference in the use of pharmacological therapy between 
men and women. 
WITHDRAWALS 
LTOT was withdrawn in 20 patients (5%) due to an 
improvement in hypoxaemia, and in seven patients (2%) 
due to a lack of co-operation. Thirty-three patients 
(8%) were withdrawn from the register as they moved 
permanently to nursing homes. 
CAUSE OF DEATH 
During follow-up, 301 patients (75%) died. Death was 
caused by respiratory disease in 77%, by cardiovascular 
disease in 5% and by both respiratory and cardiovascular 
disease in 11%. In 4% of the patients, death was due to 
other causes and in 3% respiratory and/or cardiovascular 
disease in combination with some other cause were the 
causes of death. 
DAYS SPENT IN HOSPITAL 
Men tended to spend fewer days in hospital than women 
(median value in men 19 days per year, range O-301 YS 
median value in women 27, range O-309 days per year, 
P=O.O8). The mean annual hospital admission rate during 
follow-up did not differ between the sexes (2.6 & 2.9 stays 
per year in men vs 2.8 * 3.0 admissions per year in women, 
PzO.50). Patients who died spent more days per year as 
inpatients in hospital than surviving patients (48 i 61 vs 
32 f 42 days per year, P<O.Ol). Of the patients who died, 
women tended to spend more days in hospital per year than 
men (P=O.O5). In surviving patients, there was no difference 
in days spent in hospital per year according to sex (32 * 46 
days per year in men vs 32 & 49 days per year in women, 
P>O.8). 
There was a strong correlation between days spent in 
hospital and performance status (P<O.OOl) (Table 3). Older 
patients spent a greater proportion of follow-up time in 
hospital than younger patients (P=O.O4) (Fig. 1). 
Patients receiving oral steroid medication spent more 
days per year in hospital than patients not receiving oral 
steroid medication (51 f 65 vs 36 * 46 days per year, 
P=O.Ol). This difference in inhospital care was significant in 
women (P=O.Ol), but not in men (P=O,41) (Fig. 2). An 
increase in the mean number of days of the hospital care 
periods in patients who died during follow-up explained 
this difference (14 & 12 days/hospital admission in men vs 
22 & 22 in women) (P=O.Ol), while the mean number of 
hospital admissions per year was similar (2.8 f 3.2 stays per 
year in men vs 3.1 & 3.0 stays per year in women, PzO.46). 
Fifty percent of the patients on oral steroids were also on 
oral steroid medication at follow-up after 6 months of 
LTOT. In men with oral steroids at the start of LTOT, the 
number of days spent in hospital per year was the same, 
irrespective of use of oral steroids at the 6-month follow-up 
(mean values 43 and 41 days per year with and without 
oral steroids, respectively). In women with oral steroids 
at the start of LTOT, those who were on oral steroid 
medication at the 6-month follow-up spent more days in 
TABLE 3. Days spent in hospital per year of follow-up during long-term oxygen therapy in chronic 
obstructive pulmonary disease by World Health Organization performance status class (mean f SD) 
(n=403) 
Performance status class No. patients Days per year 
0. Able to carry out normal activities 
1. Restricted in activity, but ambulatory 
2. Confined to bed for less than 50% of waking hours 
3. Confined to bed for more than 50% of waking hours 
4. Totally confined to bed 
22 25 zt 28 
210 35 i 48 
129 58 + 69 
38 61 5 61 
0 - 
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FIG. 1. Mean number of days spent in hospital per year 
of follow-up during long-term oxygen therapy in chronic 
obstructive pulmonary disease by age and sex (n=403). 
Open bars, men; solid bars, women. 
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FIG. 2. Mean number of days spent in hospital per year 
of follow-up during long-term oxygen therapy in patients 
with chronic obstructive pulmonary disease by sex and 
type of steroid medication (n=403). Open bars, men; solid 
bars, women. 
hospital per year than those who were not (mean values 76 
and 55 days per year with and without oral steroids, 
respectively). 
TABLE 4. Relative risks of mortality (RR) with 95% confi- 
dence intervals (CI) in patients with chronic obstructive 
pulmonary disease receiving long-term oxygen therapy by 
univariate analysis (n=403) 
Characteristic RR CI 
Age (years) 
110 
>70 
Sex 
Male 
Female 
Performance class 
0, 1 
2 
3, 4 
FEV, (1) 
I 0.8 in men/ 5 0.6 in women 
>0.8 in me&O.6 in women 
PaO, (air) (kPa) 
<6 
>6 
Corticosteroid medication 
None 
Inhaled 
Oral 
Digitalis medication 
Yes 
No 
1 Reference 
1.71 l-42-2.21 
1.28 1.02-1.61 
1 Reference 
1 Reference 
1.68 1.32-2.13 
3.84 2.71-5.45 
1.41 1.04-1.89 
1 Reference 
1.30 1.06-1.67 
1 Reference 
1 Reference 
0.88 0.62-1.23 
1.38 1.05-1.81 
1.28 1.01-1.62 
1 Reference 
Patients with inhaled and oral corticosteroid medication 
have been grouped with patients with oral corticosteroid 
medication only. For definitions of performance class, see 
Table 3. For definitions of abbreviations, see Table 1. 
In the multivariate analysis; days per year spent in 
hospital was significantly higher in women on oral steroid 
medication after corrections for age and performance status 
(P=O.Ol). 
There were no significant differences in days per 
year spent in hospital during follow-up according to 
smoking history, arterial blood gas tension while breathing 
air or oxygen, spirometry values, oral or inhaled 
&-agonist, theophylline, digitalis, calcium antagonist, 
diuretic or anticoagulant medication in either univariate 
analysis or multivariate analysis after corrections for age 
and performance status. 
SURVIVAL 
First-year survival was 77%, second-year survival 56% and 
third-year survival 38%. Survival was predicted by age, sex, 
FEV,, performance status, presence or absence of oral 
steroid and digitalis medication and PaO, (air) (Table 4). 
Patients below the age of 70 years had a better survival rate 
than older patients (BO.005) and women had a better 
survival rate than men (P=O.O3). 
54 K. STROM 
TABLE 5. Relative risks of mortality (RR) with 95% confidence intervals (CI) in patients with chronic 
obstructive pulmonary disease receiving long-term oxygen therapy by multivariate analysis (n =403) 
Characteristic RR 
Men Women 
CI RR CI 
Performance class 
0, 1 
2 
3, 4 
Corticosteroid medication 
None 
Inhaled corticosteroid 
Oral corticosteroid 
1 Reference 1 Reference 
1.79 1.26-2.56 1.64 1.16-2.32 
4.23 2.42-7.40 4.56 2.63-7.91 
1 Reference 1 Reference 
0.74 0.47-1.17 0.96 0.59-1.56 
1.08 0.74-1.59 1.49 1.00-2.22 
Patients with inhaled and oral corticosteroid medication have been grouped with patients with oral 
corticosteroid medication only. For definitions of performance class, see Table 3. 
Patients with an FEV, of above mean (>0.8 1 in men and 
>0.6 1 in women) had a better survival rate than patients 
with lower FEV, values (P=O.O2). Patients with a good 
performance status had a better survival rate than patients 
with a poor performance status (BO.005). Oral steroid 
medication was associated with poor survival (BO.005). 
Patients receiving digitalis medication had an increased 
mortality rate (PzO.04) as had patients with a PaO, (air) of 
below 6.0 kPa (P=O.O4). 
In the multivariate analysis, survival was significantly 
related to age (P=O.O2), performance status (P<O,OO5), sex 
(P=O.O2) and type of steroid medication (P=O.O2) but not 
to FEV,, PaO, (air) or other medications. 
Predictors of Survival in Male Patients 
In the univariate analysis, survival was related to age 
(P<O.O05) and performance status (P<O.O05). In the 
multivariate analysis, survival was related to performance 
status (P<O.O05) (Table 5). 
Predictors of Survival in Female Patients 
In the univariate analysis, survival was related to age 
(P<O.Ol), performance status (P<O.O05) and type of corti- 
costeroid medication (P=O.O2). In the multivariate analysis, 
survival was related to performance status (P<O.OO) and 
type of steroid medication (P=O.O4) (Table 5). 
Discussion 
The investigation revealed a great need for hospital care 
during LTOT, particularly in the terminal stage of the 
disease. The independent predictors of mortality coincided 
with predictors of the need for hospital care in terms of 
days per year spent in hospital. Oral corticosteroid medi- 
cation was again found as an independent predictor of 
increased mortality among women with COPD (9). It was 
also found to be a significant independent predictor of need 
of hospital care in women and apparently in the terminal 
stage, since a significant prolongation of hospital stays was 
found only in women who died during follow-up. It would 
have been of advantage to have known the dose and 
duration of oral costicosteroid therapy. These data were 
not registered but the medication at 6-month follow-up is 
known. The increase in days spent in hospital per year was 
observed in women receiving oral steroids both at the start 
of LTOT and after 6 months, suggesting that the increase in 
need of hospital care observed in women was associated 
with long-term oral steroid medication rather than with its 
use for exacerbations. The mean dose of prednisone was 
7.5 mg day - i at the start of LTOT in a later cohort of 
patients in the register. 
Inhaled corticosteroid medication was associated with 
neither a significant increase nor a decrease in mortality or 
any increase in the need for hospital care. The authors were 
therefore unable to confirm the observation that inhaled 
corticosteroids reduce the exacerbation rate in COPD (10). 
The increase in need for hospital care in elderly patients 
with COPD was limited and should not discourage the use 
of LTOT when subjective benefit is obtained. 
Selection bias caused by the lack of randomization 
probably explains some of the results. It is reasonable to 
assume that patients receiving digitalis medication were at 
greater risk. Corticosteroid medication, including inhaled 
corticosteroids, were probably prescribed for patients with 
more severe disease or a disease more liable to exacer- 
bations of COPD. There is no reason why this selection bias 
should be restricted to female patients. It is also reasonable 
to suppose that oral bronchodilator treatment might have 
been prescribed more often to patients with more severe 
disease or to patients liable to frequent exacerbations. Still, 
no indication was found that theophylline or oral & 
agonist treatment was associated with more or longer 
hospital admissions (12,14,15). The relatively small number 
of patients not receiving theophylline or oral /&-agonist 
treatment (Table 2) could have made it impossible to show 
a small effect. The lack of randomization and the fact that 
no details of the reason for hospital care apart from the 
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general term ‘respiratory disease’ was registered preclude 
definite conclusions on the reason for the longer hospital 
stays in women receiving oral steroids. It is unlikely that the 
difference in morbidity was due to an increase in suscepti- 
bility to infections since the number of hospital stays was 
essentially unaffected. Sex-related differences in susceptibil- 
ity to the side-effects of oral corticosteroids could be an 
explanation. Post-menopausal women are more liable to 
osteoporosis than men, and severe osteoporosis with mul- 
tiple thoracic spine compression fractures can lead to a 
deterioration in lung function (21). Corticosteroid-induced 
myopathy occurs in both male and female patients with 
COPD and has been associated with an increased mortality 
in hypercapnic respiratory failure (22). The authors found 
no indication of higher PaCO, values in women with oral 
steroid medication dying during follow-up than in other 
patient groups, but on the other hand, respiratory failure 
was the sole or a contributing cause of death in 88% of the 
deaths and the majority of the patients were hypercapnic. 
Investigating outcome in patients participating in a 
national register without exclusion criteria can make it 
possible to evaluate the clinical relevance of possible phar- 
macological side-effects in a whole patient population. The 
fact that no patient was excluded due to complicating 
serious disease could be one explanation why so many of 
these patients had oral bronchodilators, oral corticosteroids 
and/or digitalis. 
The independent predictors of survival in this study dif- 
fered from those of other investigations, probably because 
other factors influencing survival, such as performance 
status, were included in the multivariate analysis (23,24). 
A recent analysis of baseline data relating to COPD 
patients in the Swedish Oxygen Register, who started 
LTOT after 1 July 1992, reveals that the proportion of 
patients receiving oral steroid medication had diminished 
from one-half to one-third since the first report of increased 
mortality with this treatment (9), while the doses were the 
same in both sexes (26). Since prescriptions of the same 
dose of oral corticosteroid medication to male and female 
patients in COPD could result in a greater incidence and 
severity of side-effects in female patients, this practice 
should be debated. 
References 
1. Nocturnal Oxygen Therapy Trial Group. Continuous 
or nocturnal oxygen therapy in chronic obstructive 
lung disease. Ann Intern Med 1980; 93: 391-398. 
2. Medical Research Council Working Party. Long-term 
domiciliary oxygen therapy in chronic hypoxic car 
pulmonale complicating chronic bronchitis and emphy- 
sema. Lancet 1981; i: 681-686. 
3. McSweeney AJ, Grant I, Heaton RK, Adams KM, 
Timms RM. Life quality of patients with chronic 
obstructive pulmonary disease. Avck Intern Med 1982; 
142: 473478. 
4. Derenne J-P, Fleury B, Pariente R. Acute respiratory 
failure of chronic obstructive pulmonary disease. Am 
Rev Respir Dis 1988; 13: 100661033 (review). 
5. Petty TL, Neff TA, Creagh E et al. Outpatient oxygen 
therapy in chronic obstructive pulmonary disease. Arch 
Intern Med 1979; 139: 28-32. 
6. Strom K, Boe J. A national register for long-term 
oxygen therapy in chronic hypoxia: preliminary results. 
Eus Respir J 1988; 1: 952-958. 
7. Postma DS, Steenhuis EJ, vd Weele LT, Sluiter HJ. 
Severe chronic airflow obstruction: can corticosteroids 
slow down obstruction? Eur J Respiv Dis 1985; 67: 
56-64. 
8. Postma DS, Peters I, Steenhuis EJ, Sluiter HJ. Moder- 
ately severe chronic airflow obstruction. Can corticos- 
teroids slow down obstruction? Euv Respir J 1988; 1: 
22-26. 
9. Strom K. Survival of patients with chronic obstructive 
pulmonary disease receiving long-term domiciliary oxy- 
gen therapy. Am Rev Respiv Dis 1993; 147: 585-591. 
10. Dompeling E, v Schayck C, Grunsven PM et al. 
Slowing the deterioration of asthma and chronic 
obstructive pulmonary disease observed during bron- 
chodilator therapy by adding inhaled corticosteroids. 
Ann Intern Med 1993; 118: 770-778. 
11. Esposito AL, Poirier WJ, Clark LA. The cardiac gly- 
coside digoxin disrupts host defense in experimental 
pneumococcal pneumonia by impairing neutrophil 
mobilization. Am Rev Respir Dis 1989; 140: 1590-1594. 
12. Llewellyn-Jones CG, Stockley RA. The effects of beta,- 
agonists and methylxanthines on neutrophil function in 
vitro. Eur Respir J 1994; 7: 1560-1566. 
13. Sakuma T, Okaniwa G, Nakada T, Nishimura T, 
Fujimura S, Matthay MA. Alveolar fluid clearance in 
the resected human lung. Am J Respiv Cvit Care Med 
1994; 150: 305-310. 
14. Nelson S, Summer WR, Jakob GJ. Aminophylline- 
induced suppression of pulmonary antibacterial 
defences. Am Rev Respir Dis 1985; 131: 923-927. 
15. O’Neill SJ, Siter DS, Klass DJ, Taraska VA, Kepson 
W, Mitenko PA. The pulmonary disposition of theo- 
phylline and its influence on human alveolar macro- 
phage bacterial function. Am Rev Respiv Dis 1986; 134: 
1225-1228. 
16. World Health Organization. Handbook for reporting 
results of cancer treatment. WHO offset publication no 
48. Geneva: WHO, 1979. 
17. Strom K, Boe J, The Swedish Society of Chest Medi- 
cine. Quality assessment and predictors of survival in 
long-term oxygen therapy. Euv Respiv J 1991; 4: 50-58. 
18. Gustavsson L. Quest: A Data Programmefor Statistical 
and Epidemiological Data Analysis. University of 
Umea, 1991. 
19. Peto R, Pike MC, Armitage P, Breslow NE et al. 
Design and analysis of randomized clinical trials 
requiring prolonged observation of each patient. BY J 
Cancer 1977; 35: l-39. 
20. Miettinen OSA. Estimatability and estimation in case- 
reference studies. Am J Epidemiol 1976; 103: 226-235. 
21. Lech JA, Dulberg C, Kellie S, Pattee L, Gay 5. Rela- 
tionship of lung function to severity of osteoporosis in 
women. Am Rev Respiv Dis 1990; 141: 68-71. 
56 K. STROM 
22. Decramer M, Brock V, Dom R. Functional and histo- 
logic picture of steroid-induced myopathy in chronic 
obstructive pulmonary disease. Am J Respir Crit Cave 
Med 1996; 153: 195881964. 
23. Skwarski K, MacNee W, Wraith PK, Sliwinski P? 
Zielinski J. Predictors of survival in patients with 
chronic obstructive pulmonary disease treated with 
long-term oxygen therapy. Chest 1991; 100: 1522-l 527. 
24. Dubois P, Jamart J, Machiels J, Smeets F, Lulling J. 
Prognosis of severely hypoxemic patients receiving 
long-term oxygen therapy. Chest 1994; 105: 469474. 
25. Strom K, The Swedish Society of Chest Medicine. Oral 
steroid medication and hospital care in patients with 
chronic obstructive pulmonary disease receiving 
long-term oxygen therapy. H,vgiea 1994; 130: 227 (in 
Swedish). 
